CO5261534A1 - Uso de inhibidores de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsomales - Google Patents
Uso de inhibidores de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsomalesInfo
- Publication number
- CO5261534A1 CO5261534A1 CO00085765A CO00085765A CO5261534A1 CO 5261534 A1 CO5261534 A1 CO 5261534A1 CO 00085765 A CO00085765 A CO 00085765A CO 00085765 A CO00085765 A CO 00085765A CO 5261534 A1 CO5261534 A1 CO 5261534A1
- Authority
- CO
- Colombia
- Prior art keywords
- microsomal
- animal
- secretion
- apolipoprotein
- inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 230000003228 microsomal effect Effects 0.000 title abstract 4
- 230000028327 secretion Effects 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 abstract 5
- 102000007592 Apolipoproteins Human genes 0.000 abstract 3
- 108010071619 Apolipoproteins Proteins 0.000 abstract 3
- 239000000883 anti-obesity agent Substances 0.000 abstract 3
- 229940125710 antiobesity agent Drugs 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 230000000968 intestinal effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000003981 vehicle Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16454799P | 1999-11-10 | 1999-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5261534A1 true CO5261534A1 (es) | 2003-03-31 |
Family
ID=22595001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00085765A CO5261534A1 (es) | 1999-11-10 | 2000-11-10 | Uso de inhibidores de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsomales |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1099439A3 (enExample) |
| JP (1) | JP2001172180A (enExample) |
| KR (1) | KR20010051558A (enExample) |
| AU (1) | AU6968700A (enExample) |
| CA (1) | CA2324800A1 (enExample) |
| CO (1) | CO5261534A1 (enExample) |
| HU (1) | HUP0004461A3 (enExample) |
| IL (1) | IL139448A0 (enExample) |
| NZ (1) | NZ508059A (enExample) |
| PE (1) | PE20010705A1 (enExample) |
| ZA (1) | ZA200006419B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200502496B (en) | 2002-02-28 | 2005-10-12 | Japan Tobacco Inc | Ester compound and medicinal use thereof. |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| EP1669345A4 (en) | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | ESTER DERIVATIVE AND MEDICAL USE THEREOF |
| US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
| US20060084636A1 (en) * | 2004-10-18 | 2006-04-20 | Maria Alemany | Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same |
| KR20070072888A (ko) * | 2004-10-25 | 2007-07-06 | 니뽄 다바코 산교 가부시키가이샤 | 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법 |
| KR101129456B1 (ko) * | 2004-10-25 | 2012-03-28 | 니뽄 다바코 산교 가부시키가이샤 | 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법 |
| EP2687507B1 (en) * | 2011-03-14 | 2016-03-09 | Taisho Pharmaceutical Co., Ltd. | Nitrogen-containing condensed heterocyclic compound |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU218419B (hu) * | 1992-03-06 | 2000-08-28 | E.R. Squibb And Sons, Inc. | Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások |
| US5474993A (en) * | 1994-06-14 | 1995-12-12 | Sterling Winthrop, Inc. | Lactam inhibitors of cholesterol esterase |
| WO1996040640A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| DK0902785T3 (da) * | 1996-04-30 | 2002-10-07 | Pfizer | Fremgangsmåder og mellemprodukter til fremstilling af 4'-trifluormethylbiphenyl-2-carboxylsyre-[2-(2H-[1,2,4]triazol-3-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]amid |
| TR199901180T2 (xx) * | 1996-11-27 | 1999-08-23 | Pfizer Inc. | Apo B-Salg�lama/MTP inhibit�r amidler. |
| US5968950A (en) * | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
| IL133201A0 (en) * | 1998-12-04 | 2001-03-19 | Pfizer Prod Inc | Lowering blood levels of lipoproten (a) |
-
2000
- 2000-10-31 CA CA002324800A patent/CA2324800A1/en not_active Abandoned
- 2000-11-02 IL IL13944800A patent/IL139448A0/xx unknown
- 2000-11-02 AU AU69687/00A patent/AU6968700A/en not_active Abandoned
- 2000-11-03 EP EP00309721A patent/EP1099439A3/en not_active Withdrawn
- 2000-11-08 ZA ZA200006419A patent/ZA200006419B/xx unknown
- 2000-11-09 HU HU0004461A patent/HUP0004461A3/hu unknown
- 2000-11-09 KR KR1020000066367A patent/KR20010051558A/ko not_active Ceased
- 2000-11-09 NZ NZ508059A patent/NZ508059A/xx unknown
- 2000-11-10 JP JP2000342892A patent/JP2001172180A/ja active Pending
- 2000-11-10 CO CO00085765A patent/CO5261534A1/es not_active Application Discontinuation
- 2000-11-10 PE PE2000001207A patent/PE20010705A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0004461A3 (en) | 2004-04-28 |
| HUP0004461A2 (hu) | 2001-10-28 |
| EP1099439A2 (en) | 2001-05-16 |
| KR20010051558A (ko) | 2001-06-25 |
| JP2001172180A (ja) | 2001-06-26 |
| IL139448A0 (en) | 2001-11-25 |
| ZA200006419B (en) | 2002-05-08 |
| NZ508059A (en) | 2002-11-26 |
| HU0004461D0 (enExample) | 2001-01-29 |
| EP1099439A3 (en) | 2003-03-26 |
| CA2324800A1 (en) | 2001-05-10 |
| AU6968700A (en) | 2001-05-17 |
| PE20010705A1 (es) | 2001-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2528384T3 (es) | Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación | |
| AR034900A1 (es) | Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica | |
| CO5261582A1 (es) | Composiciones de valdecoxib | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| AR044039A1 (es) | Combinaciones antineoplasicas | |
| NO326660B1 (no) | Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene | |
| AR090677A2 (es) | Preparacion farmaceutica que contiene oxicodona y naloxona | |
| CO4970819A1 (es) | Tratamiento de disfuncion sexual femenina en una hembra humana | |
| EE05423B1 (et) | IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon | |
| DK1383752T3 (da) | Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser | |
| ECSP045025A (es) | Combinación de opioides seleccionados con antagonistas muscarnicos para el tratamiento de la incontinencia urinaria | |
| AR053541A1 (es) | Combinacion de xolair con agente inmunosupresor | |
| AR019699A1 (es) | Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico | |
| GB2431346B (en) | A combination composition comprising paracetamol and ibuprofen | |
| BR0306732A (pt) | Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico | |
| AR014640A1 (es) | UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE. | |
| AR011437A1 (es) | Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento. | |
| AR036321A1 (es) | Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. | |
| EP1099439A3 (en) | Use of apo B secretion/MTP inhibitors | |
| EA200300639A1 (ru) | Применение sarp-1 для лечения и/или предупреждения склеродермии | |
| EP1303520A4 (en) | THERAPEUTIC COMPOUNDS AND METHODS | |
| AR043016A2 (es) | Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida | |
| CO5271688A1 (es) | Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales | |
| UY26648A1 (es) | Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |